The Discriminatory Value of CYP2D6 Genotyping in Predicting the Dextromethorphan/Dextrorphan Phenotype in Women with Breast Cancer

Breast care

Urs Breitenstein¹  Athanasios Vergopoulos¹  Wolfgang Joechle¹  Andreas Trojan¹  Christoph Rageth¹  Burkhardt Seifert¹ 

[1] aOnkoZentrum, Klinik im Park, Zürich, University Hospital of Zürich, Switzerland

关键词: CYP2D6;    Phenotype;    Genotype;    Dextromethorphan/Dextrorphan;    Breast cancer;   

DOI  :  10.1159/000336551

学科分类：泌尿医学

来源: S Karger AG

【 摘 要 】

The growth inhibitory effect of tamoxifen is used for the treatment of breast cancer. Tamoxifen efficacy is mediated by its biotransformation, predominantly via the cytochrome P450 2D6 (CYP2D6) isoenzyme, to the active metabolite endoxifen. We investigated the relationship of CYP2D6 genotypes to the metabolism of dextromethorphan (DM), which is frequently used as a surrogate marker for the formation of endoxifen.

【 授权许可】

Unknown